<p>Oric Pharmaceuticals（納斯達克代碼：ORIC - 獲取免費報告）的股票在週一發佈的報告中被 Wedbush 的分析師重申了 “跑贏大盤” 的評級，RTT News 報道。他們目前對該股票的目標價為 20.00 美元。Wedbush 的目標價暗示該公司股價有 49.25% 的潛在上漲空間。</p>
<p>其他股票分析師也對該公司發佈了研究報告。Guggenheim 在 9 月 4 日（星期四）發佈的報告中開始覆蓋 Oric Pharmaceuticals。他們對該股票設定了 “買入” 評級和 18.00 美元的目標價。Zacks Research 在 8 月 12 日（星期二）的研究報告中將 Oric Pharmaceuticals 的評級上調至 “持有”。摩根大通在 8 月 14 日（星期四）的研究報告中將 Oric Pharmaceuticals 的目標價從 20.00 美元下調至 17.00 美元，並對該股票設定了 “增持” 評級。LADENBURG THALM/SH SH 在 7 月 8 日（星期二）的報告中開始覆蓋 Oric Pharmaceuticals。他們對該公司發佈了 “買入” 評級和 15.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日（星期三）的報告中重申了對 Oric Pharmaceuticals 股票的 “賣出（d-）” 評級。八位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Oric Pharmaceuticals 的平均評級為 “適度買入”，平均目標價為 17.29 美元。</p>
<p>獲取 <strong>Oric Pharmaceuticals</strong> 的提醒：</p>
<p><strong>查看我們對 ORIC 的最新分析</strong></p>
<h2>Oric Pharmaceuticals 股票表現</h2>
<p>ORIC 股票在週一的午盤交易中上漲 0.30 美元，達到 13.40 美元。該公司交易了 1,265,268 股，而其平均交易量為 1,545,989 股。該公司的市值為 13 億美元，市盈率為-7.09，貝塔值為 1.68。Oric Pharmaceuticals 的 1 年最低價為 3.90 美元，1 年最高價為 14.93 美元。該股票的 50 日簡單移動平均線為 11.48 美元，200 日簡單移動平均線為 9.40 美元。</p>
<p>Oric Pharmaceuticals（納斯達克代碼：ORIC - 獲取免費報告）最近在 8 月 12 日（星期二）發佈了其財報。該公司報告本季度每股收益為（0.47 美元），低於分析師一致預期的（0.46 美元），差距為（0.01 美元）。研究分析師平均預計 Oric Pharmaceuticals 在當前年度的每股收益為-2.17 美元。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，首席財務官 Dominic Piscitelli 在 10 月 6 日（星期一）以 14.52 美元的平均價格出售了 11,000 股該公司的股票，總價值為 159,720.00 美元。出售完成後，首席財務官持有該公司 48,317 股，價值約為 701,562.84 美元。此次交易代表其持股比例減少了 18.54%。該交易已在證券交易委員會的法律文件中披露，相關信息可通過此鏈接訪問。此外，首席執行官 Jacob Chacko 在 9 月 22 日（星期一）出售了 125,000 股 Oric Pharmaceuticals 的股票，平均價格為 10.80 美元，總交易額為 1,350,000.00 美元。出售完成後，首席執行官直接持有該公司 656,419 股，價值約為 7,089,325.20 美元。此次交易使其持股比例減少了 16.00%。該交易的披露信息可在此找到。在過去一個季度，內部人士出售了 261,000 股公司股票，價值為 3,024,703 美元。當前 5.55% 的股票由內部人士持有。</p>
<h2>機構投資者對 Oric Pharmaceuticals 的看法</h2>
<p>一些機構投資者最近增加或減少了對該公司的持股。SG Americas Securities LLC 在第三季度購買了 Oric Pharmaceuticals 的新股份，價值約為 216,000 美元。KLP Kapitalforvaltning AS 在第三季度收購了 Oric Pharmaceuticals 的新股份，價值為 85,000 美元。Squarepoint Ops LLC 在第二季度購買了 Oric Pharmaceuticals 的新股份，價值為 1,084,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Oric Pharmaceuticals 的持股增加了 1,293.0%。Tower Research Capital LLC TRC 現在擁有該公司 11,757 股股票，價值 119,000 美元，此前在該期間內又收購了 10,913 股。最後，Eventide Asset Management LLC 在第二季度收購了 Oric Pharmaceuticals 的新股份，價值為 9,657,000 美元。對沖基金和其他機構投資者目前持有該公司 95.05% 的股票。</p>
<h2>關於 Oric Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>ORIC Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於在美國發現和開發癌症治療藥物。其臨牀階段的產品候選包括 ORIC-114，這是一種可穿透大腦的口服生物可用不可逆抑制劑，目前正在進行 1b 期研究，旨在選擇性靶向表皮生長因子受體和人類表皮生長因子受體 2，對外顯子 20 插入突變具有高效能；ORIC-944，是一種針對前列腺癌的多梳抑制複合體 2 的別構抑制劑，目前正在進行 1b 期研究；以及 ORIC-533，一種口服生物可用的小分子 CD73 抑制劑，目前正在進行 1b 期研究，旨在開發用於化療和免疫治療耐藥的治療方案。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Oric Pharmaceuticals</li>
<li>如何計算通貨膨脹率</li>
<li>增長選擇：三隻低成本股票可能翻倍</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>這三隻被打壓的股票準備反彈嗎？</li>
<li>技術股票解析：關於科技你需要知道的</li>
<li>特朗普引發的量子股票反彈是否有持續性？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JJQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JJQw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Oric Pharmaceuticals 嗎？</h2>
<p>在考慮 Oric Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Oric Pharmaceuticals 並不在名單上。</p>
<p>雖然 Oric Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ORIC

<p>Wedbush 重申了對 ORIC Pharmaceuticals（NASDAQ:ORIC）的 “跑贏大盤” 評級，目標價格為 20.00 美元，暗示潛在上漲空間為 49.25%。其他分析師的評級各不相同，平均目標價格為 17.29 美元。該股票交易價格為 13.40 美元，市值為 13 億美元。最近的內部交易包括首席財務官 Dominic Piscitelli 和首席執行官 Jacob Chacko 出售股份，表明他們的持股減少。機構投資者持有 95.05% 的股份，反映出對該公司的強烈興趣</p>

<p>Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report)'s stock had its &#34;outperform&#34; rating restated by analysts at Wedbush in a report issued on Monday,RTT News reports. They presently have a $20.00 price objective on the stock. Wedbush's price target would suggest a potential upside of 49.25% from the company's previous close.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals（納斯達克代碼：ORIC - 獲取免費報告）的股票在週一發佈的報告中被 Wedbush 的分析師重申了 “跑贏大盤” 的評級，RTT News 報道。他們目前對該股票的目標價為 20.00 美元。Wedbush 的目標價暗示該公司股價有 49.25% 的潛在上漲空間。</p>
</div><p>Other equities analysts have also issued research reports about the company. Guggenheim started coverage on Oric Pharmaceuticals in a report on Thursday, September 4th. They set a &#34;buy&#34; rating and a $18.00 price objective on the stock. Zacks Research upgraded Oric Pharmaceuticals to a &#34;hold&#34; rating in a research note on Tuesday, August 12th. JPMorgan Chase &amp; Co. cut their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an &#34;overweight&#34; rating on the stock in a research report on Thursday, August 14th. LADENBURG THALM/SH SH assumed coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They issued a &#34;buy&#34; rating and a $15.00 price objective for the company. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Oric Pharmaceuticals in a report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Oric Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and an average target price of $17.29.</p>
<div class="lb-trans"><p>其他股票分析師也對該公司發佈了研究報告。Guggenheim 在 9 月 4 日（星期四）發佈的報告中開始覆蓋 Oric Pharmaceuticals。他們對該股票設定了 “買入” 評級和 18.00 美元的目標價。Zacks Research 在 8 月 12 日（星期二）的研究報告中將 Oric Pharmaceuticals 的評級上調至 “持有”。摩根大通在 8 月 14 日（星期四）的研究報告中將 Oric Pharmaceuticals 的目標價從 20.00 美元下調至 17.00 美元，並對該股票設定了 “增持” 評級。LADENBURG THALM/SH SH 在 7 月 8 日（星期二）的報告中開始覆蓋 Oric Pharmaceuticals。他們對該公司發佈了 “買入” 評級和 15.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日（星期三）的報告中重申了對 Oric Pharmaceuticals 股票的 “賣出（d-）” 評級。八位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Oric Pharmaceuticals 的平均評級為 “適度買入”，平均目標價為 17.29 美元。</p>
</div><p>Get <strong>Oric Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Oric Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>View Our Latest Analysis on ORIC</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ORIC 的最新分析</strong></p>
</div><h2>Oric Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Oric Pharmaceuticals 股票表現</h2>
</div><p>ORIC stock traded up $0.30 during midday trading on Monday, reaching $13.40. 1,265,268 shares of the company were exchanged, compared to its average volume of 1,545,989. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -7.09 and a beta of 1.68. Oric Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $14.93. The stock's 50-day simple moving average is $11.48 and its 200 day simple moving average is $9.40.</p>
<div class="lb-trans"><p>ORIC 股票在週一的午盤交易中上漲 0.30 美元，達到 13.40 美元。該公司交易了 1,265,268 股，而其平均交易量為 1,545,989 股。該公司的市值為 13 億美元，市盈率為-7.09，貝塔值為 1.68。Oric Pharmaceuticals 的 1 年最低價為 3.90 美元，1 年最高價為 14.93 美元。該股票的 50 日簡單移動平均線為 11.48 美元，200 日簡單移動平均線為 9.40 美元。</p>
</div><p>Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). On average, research analysts anticipate that Oric Pharmaceuticals will post -2.17 earnings per share for the current year.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals（納斯達克代碼：ORIC - 獲取免費報告）最近在 8 月 12 日（星期二）發佈了其財報。該公司報告本季度每股收益為（0.47 美元），低於分析師一致預期的（0.46 美元），差距為（0.01 美元）。研究分析師平均預計 Oric Pharmaceuticals 在當前年度的每股收益為-2.17 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, CFO Dominic Piscitelli sold 11,000 shares of the firm's stock in a transaction on Monday, October 6th. The shares were sold at an average price of $14.52, for a total value of $159,720.00. Following the completion of the sale, the chief financial officer owned 48,317 shares in the company, valued at approximately $701,562.84. This trade represents a 18.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, CEO Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $10.80, for a total transaction of $1,350,000.00. Following the completion of the sale, the chief executive officer directly owned 656,419 shares in the company, valued at approximately $7,089,325.20. The trade was a 16.00% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 261,000 shares of company stock worth $3,024,703. 5.55% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席財務官 Dominic Piscitelli 在 10 月 6 日（星期一）以 14.52 美元的平均價格出售了 11,000 股該公司的股票，總價值為 159,720.00 美元。出售完成後，首席財務官持有該公司 48,317 股，價值約為 701,562.84 美元。此次交易代表其持股比例減少了 18.54%。該交易已在證券交易委員會的法律文件中披露，相關信息可通過此鏈接訪問。此外，首席執行官 Jacob Chacko 在 9 月 22 日（星期一）出售了 125,000 股 Oric Pharmaceuticals 的股票，平均價格為 10.80 美元，總交易額為 1,350,000.00 美元。出售完成後，首席執行官直接持有該公司 656,419 股，價值約為 7,089,325.20 美元。此次交易使其持股比例減少了 16.00%。該交易的披露信息可在此找到。在過去一個季度，內部人士出售了 261,000 股公司股票，價值為 3,024,703 美元。當前 5.55% 的股票由內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Oric Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Oric Pharmaceuticals 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in shares of Oric Pharmaceuticals during the 3rd quarter worth approximately $216,000. KLP Kapitalforvaltning AS acquired a new position in Oric Pharmaceuticals during the third quarter worth $85,000. Squarepoint Ops LLC purchased a new position in Oric Pharmaceuticals in the second quarter worth $1,084,000. Tower Research Capital LLC TRC lifted its holdings in Oric Pharmaceuticals by 1,293.0% in the second quarter. Tower Research Capital LLC TRC now owns 11,757 shares of the company's stock valued at $119,000 after acquiring an additional 10,913 shares during the period. Finally, Eventide Asset Management LLC acquired a new stake in Oric Pharmaceuticals in the second quarter valued at $9,657,000. Hedge funds and other institutional investors own 95.05% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者最近增加或減少了對該公司的持股。SG Americas Securities LLC 在第三季度購買了 Oric Pharmaceuticals 的新股份，價值約為 216,000 美元。KLP Kapitalforvaltning AS 在第三季度收購了 Oric Pharmaceuticals 的新股份，價值為 85,000 美元。Squarepoint Ops LLC 在第二季度購買了 Oric Pharmaceuticals 的新股份，價值為 1,084,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Oric Pharmaceuticals 的持股增加了 1,293.0%。Tower Research Capital LLC TRC 現在擁有該公司 11,757 股股票，價值 119,000 美元，此前在該期間內又收購了 10,913 股。最後，Eventide Asset Management LLC 在第二季度收購了 Oric Pharmaceuticals 的新股份，價值為 9,657,000 美元。對沖基金和其他機構投資者目前持有該公司 95.05% 的股票。</p>
</div><h2>About Oric Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Oric Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.</p>
<div class="lb-trans"><p>ORIC Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於在美國發現和開發癌症治療藥物。其臨牀階段的產品候選包括 ORIC-114，這是一種可穿透大腦的口服生物可用不可逆抑制劑，目前正在進行 1b 期研究，旨在選擇性靶向表皮生長因子受體和人類表皮生長因子受體 2，對外顯子 20 插入突變具有高效能；ORIC-944，是一種針對前列腺癌的多梳抑制複合體 2 的別構抑制劑，目前正在進行 1b 期研究；以及 ORIC-533，一種口服生物可用的小分子 CD73 抑制劑，目前正在進行 1b 期研究，旨在開發用於化療和免疫治療耐藥的治療方案。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Oric Pharmaceuticals</li>
<li>How to Calculate Inflation Rate</li>
<li>Growth Picks: 3 Low-Cost Stocks That Could Double in Value</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Are These 3 Beaten-Down Stocks Ready to Rebound?</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Does the Trump-Induced Quantum Stock Rally Have Legs?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Oric Pharmaceuticals</li>
<li>如何計算通貨膨脹率</li>
<li>增長選擇：三隻低成本股票可能翻倍</li>
<li>為什麼投資 5G？如何投資 5G 股票</li>
<li>這三隻被打壓的股票準備反彈嗎？</li>
<li>技術股票解析：關於科技你需要知道的</li>
<li>特朗普引發的量子股票反彈是否有持續性？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JJQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ORIC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Oric Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Oric Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Oric Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Oric Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Oric Pharmaceuticals 並不在名單上。</p>
</div><p>While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Oric Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Wedbush 重申對 ORIC Pharmaceuticals（NASDAQ:ORIC）的 “跑贏大盤” 評級